SMTISanara MedTech Inc.
The Read
9% on Q1 2026 results showing 19% revenue growth, 93%+ gross margins, and its first GAAP profit after exiting the THP segment.
The schedule
- Tue20Oct
As SMTI manages $48.4M in debt against $13.6M in cash, the risk of a dilutive equity raise or expensive debt refinancing comes into focus.
- Sat14Nov
Around early 2027, SMTI is expected to have additional clinical or real-world data and commercial traction metrics for its advanced biologics wound-care portfolio. From a base of $18.50, stronger evidence of efficacy and adoption could unlock a premium growth multiple.
- Mon8Feb
Q3 2026 earnings will focus on SMTI's late-year revenue execution and preliminary visibility into FY 2027 growth targets.
- Sun14Feb
The Q4 print and official 2027 financial outlook will be a major catalyst, as historical guidance resets in this space are highly challenging.
- Tue11May
First-quarter results for 2027 will test Sanara's early execution on its annual outlook and pipeline monetization.
Past
- Mon10Aug
Actual outcome: Bull · $34.15 at outcome
Sanara MedTech reported Q2 2026 earnings of $0.05 per share, beating estimates and marking a significant turnaround from a $0.23 loss a year ago. The stock maintained its position well above the bull target, trading around $34.15, primarily due to the recently announced proposed acquisition of the company by MiMedx Group. The combination of a swing to profitability and the pending buyout deal cemented the stock's massive gains.
The Q2 2026 earnings release will serve as a critical gauge of Sanara's resilience against competitive headwinds and its ability to narrow its net losses.
- Wed15Jul
Actual outcome: Bull · $30.25 at outcome
Sanara MedTech successfully defended its market share against feared competitor product launches, maintaining its strong revenue growth and pricing power in the advanced wound care market. The lack of material impact from competitive pricing aggression reassured investors of the company's entrenched market position, driving a 23% rally well past the bull target.
Potential competitive product entries or price aggression in the advanced wound care market could pressure Sanara's 18.6% YoY revenue growth rate.
- Tue12May
Actual outcome: Bull · $22.72 at outcome
Sanara MedTech delivered a strong Q1 2026 report, featuring 19% revenue growth, gross margins exceeding 93%, and its first GAAP profit from continuing operations in years at $0.04 per share. The strategic discontinuation of the THP segment materially improved profitability and operating margins, shifting the narrative from cash burn to profitable growth and driving the stock well past the $21.50 bull target.
Q1 2026 results are the first clean quarter after a year of earnings noise and balance sheet expansion. With revenue growth running in the mid-single digits and the stock at $16.97 near its 52-week low, the market will focus on whether margin stabilization and cash generation can support the current $232.9M enterprise value.
- Tue24Mar
Actual outcome: Bear · $16.96 at outcome
Sanara MedTech reported Q4 earnings of $0.04 per share, significantly missing the consensus estimate of $0.11, which triggered a 6.2% decline in the stock price. While the company reaffirmed its 2026 financial guidance, the earnings miss overshadowed the outlook and kept the price trading near the bear floor as investors remained cautious following previous net loss anomalies.
Release of fiscal year results with heavy focus on explaining the $30M Q3 net loss anomaly and 2026 revenue guidance.
